title: [Imatinib and solid tumours].
abstract: Imatinib mesylate (Gleevec, Glivec, Novartis, Basel, Switzerland) is a small molecule inhibitor of the tyrosine kinase c-abl, c-kit and the platelet derived growth factor receptor (PDGFR). Imatinib was developed for the treatment of chronic myeloid leukaemia (CML) but was approved both in Europe and the US fro the treatment of CML and gastrointestinal stromal tumors (GIST). Given its activity against both c-kit and PDGFR kinases and its remarkable safety profile, imatinib has been 'tried' in several solid tumors; results however have often been deceiving. We review the current data regarding the activity of imatinib in solid tumors, including GIST.
authors.affiliation: Unité de jour d'oncologie médicale multidisciplinaire, pavillon E, Hôpital Edouard-Herriot, 5 place d'Arsonval, 69003 Lyon, France.
authors.forename: Samia
authors.initials: S
authors.lastname: Arifi
authors.forename: Hiba
authors.initials: H
authors.lastname: El Sayadi
authors.forename: Armelle
authors.initials: A
authors.lastname: Dufresne
authors.forename: Isabelle
authors.initials: I
authors.lastname: Ray-Coquard
authors.forename: Jérôme
authors.initials: J
authors.lastname: Fayette
authors.forename: Pierre
authors.initials: P
authors.lastname: Méeus
authors.forename: Dominique
authors.initials: D
authors.lastname: Ranchère
authors.forename: Anne-Valérie
authors.initials: AV
authors.lastname: Decouvelaere
authors.forename: Laurent
authors.initials: L
authors.lastname: Alberti
authors.forename: Séverine
authors.initials: S
authors.lastname: Tabone-Eglinger
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Blay
authors.forename: Philippe
authors.initials: P
authors.lastname: Cassier
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D018223:Dermatofibrosarcoma / Q000188:drug therapy; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D009369:Neoplasms / Q000188:drug therapy*; D016609:Neoplasms, Second Primary / Q000139:chemically induced; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D016315:Proto-Oncogene Proteins c-abl / Q000037:antagonists & inhibitors; D019009:Proto-Oncogene Proteins c-kit / Q000378:metabolism; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D017479:Receptors, Platelet-Derived Growth Factor / Q000378:metabolism; D012878:Skin Neoplasms / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit; D017479:Receptors, Platelet-Derived Growth Factor; D016044:Fusion Proteins, bcr-abl; D016315:Proto-Oncogene Proteins c-abl